Treatment of diverticulitis; medical management & surgical management.

E. G. Wakefield,R. Turnbull

DOI: https://doi.org/10.1080/00325481.1958.11692120

1958-06-01

Postgraduate Medicine

Abstract:

What problem does this paper attempt to address?

Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial

Conor D Tweed,Rodney Dawson,Divan A Burger,Almari Conradie,Angela M Crook,Carl M Mendel,Francesca Conradie,Andreas H Diacon,Nyanda E Ntinginya,Daniel E Everitt,Frederick Haraka,Mengchun Li,Christo H van Niekerk,Alphonse Okwera,Mohammed S Rassool,Klaus Reither,Modulakgotla A Sebe,Suzanne Staples,Ebrahim Variava,Melvin Spigelman

DOI: https://doi.org/10.1016/s2213-2600(19)30366-2

IF: 102.642

2019-12-01

The Lancet Respiratory Medicine

Abstract:<h2 class="section-title u-h3 u-margin-l-top u-margin-xs-bottom">Summary</h2><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>New anti-tuberculosis regimens that are shorter, simpler, and less toxic than those that are currently available are needed as part of the global effort to address the tuberculosis epidemic. We aimed to investigate the bactericidal activity and safety profile of combinations of bedaquiline, pretomanid, moxifloxacin, and pyrazinamide in the first 8 weeks of treatment of pulmonary tuberculosis.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>In this multicentre, open-label, partially randomised, phase 2b trial, we prospectively recruited patients with drug-susceptible or rifampicin-resistant pulmonary tuberculosis from seven sites in South Africa, two in Tanzania, and one in Uganda. Patients aged 18 years or older with sputum smear grade 1+ or higher were eligible for enrolment, and a molecular assay (GeneXpert or MTBDR<em>plus</em>) was used to confirm the diagnosis of tuberculosis and to distinguish between drug-susceptible and rifampicin-resistant tuberculosis. Patients who were HIV positive with a baseline CD4 cell count of less than 100 cells per uL were excluded. Patients with drug-susceptible tuberculosis were randomly assigned (1:1:1) using numbered treatment packs with sequential allocation by the pharmacist to receive 56 days of treatment with standard tuberculosis therapy (oral isoniazid, rifampicin, pyrazinamide, and ethambutol; HRZE), or pretomanid (oral 200 mg daily) and pyrazinamide (oral 1500 mg daily) with either oral bedaquiline 400 mg daily on days 1–14 then 200 mg three times per week (B<sub>load</sub>PaZ) or oral bedaquiline 200 mg daily (B<sub>200</sub>PaZ). Patients with rifampicin-resistant tuberculosis received 56 days of the B<sub>200</sub>PaZ regimen plus moxifloxacin 400 mg daily (BPaMZ). All treatment groups were open label, and randomisation was not stratified. Patients, trial investigators and staff, pharmacists or dispensers, laboratory staff (with the exception of the mycobacteriology laboratory staff), sponsor staff, and applicable contract research organisations were not masked. The primary efficacy outcome was daily percentage change in time to sputum culture positivity (TTP) in liquid medium over days 0–56 in the drug-susceptible tuberculosis population, based on non-linear mixed-effects regression modelling of log<sub>10</sub> (TTP) over time. The efficacy analysis population contained patients who received at least one dose of medication and who had efficacy data available and had no major protocol violations. The safety population contained patients who received at least one dose of medication. This study is registered with <a href="http://ClinicalTrials.gov">ClinicalTrials.gov</a>, <a href="https://clinicaltrials.gov/show/NCT02193776">NCT02193776</a>, and all patients have completed follow-up.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Findings</h3><p>Between Oct 24, 2014, and Dec 15, 2015, we enrolled 180 patients with drug-susceptible tuberculosis (59 were randomly assigned to B<sub>load</sub>PaZ, 60 to B<sub>200</sub>PaZ, and 61 to HRZE) and 60 patients with rifampicin-resistant tuberculosis. 57 patients in the B<sub>load</sub>PaZ group, 56 in the B<sub>200</sub>PaZ group, and 59 in the HRZE group were included in the primary analysis. B<sub>200</sub>PaZ produced the highest daily percentage change in TTP (5·17% [95% Bayesian credibility interval 4·61–5·77]), followed by B<sub>load</sub>PaZ (4·87% [4·31–5·47]) and HRZE group (4·04% [3·67–4·42]). The bactericidal activity in B<sub>200</sub>PaZ and B<sub>load</sub>PaZ groups versus that in the HRZE group was significantly different. Higher proportions of patients in the B<sub>load</sub>PaZ (six [10%] of 59) and B<sub>200</sub>PaZ (five [8%] of 60) groups discontinued the study drug than in the HRZE group (two [3%] of 61) because of adverse events. Liver enzyme elevations were the most common grade 3 or 4 adverse events and resulted in the withdrawal of ten patients (five [8%] in the B<sub>load</sub>PaZ group, three [5%] in the B<sub>200</sub>PaZ group, and two [3%] in the HRZE group). Serious treatment-related adverse events affected two (3%) patients in the B<sub>load</sub>PaZ group and one (2%) patient in the HRZE group. Seven (4%) patients with drug-susceptible tuberculosis died and four (7%) patients with rifampicin-resistant tuberculosis died. None of the deaths were considered to be related to treatment.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Interpretation</h3><p>B<sub>200</sub>PaZ is a promising regimen to treat patients with drug-susceptible tuberculosis. The bactericidal activity of both these regimens suggests that they have the potential to shorten treatment, and the simplified dosing schedule of B<sub>200</sub>PaZ could improve treatment adherence in the field. Howev <p>-Abstract Truncated-</p>
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

Bern-Thomas Nyang'wa,Catherine Berry,Emil Kazounis,Ilaria Motta,Nargiza Parpieva,Zinaida Tigay,Ronelle Moodliar,Matthew Dodd,Varvara Solodovnikova,Irina Liverko,Shakira Rajaram,Mohammed Rassool,Timothy McHugh,Melvin Spigelman,David A Moore,Koert Ritmeijer,Philipp du Cros,Katherine Fielding,TB-PRACTECAL team,Erin Da Costa,Nathalie Lachenal,Nicola James,Animesh Sinha,Kristen LeBeau,Emma Douch,Pascal Jolivert,Hannah Poulsom,Marion Conijn,Sean King,Hannah Spencer,Emma Cunden,Charlotte Batts,Thuy Vuong,Sebastian Dietrich,Melissa McRae,Sidney Wong,Eugene Sun,Morounfolu Olugbosi,Leslie Shanks,Michael Hughes,Payam Nahid,Johnstone Kumwenda,Todd Lorenz,Suman Majumdar,Robert C Horsburgh,Eric Nuermberger,Graeme Meintjes,Kathleen Eisenach,Christian Lienhardt,Andrew Nunn,Christoph Lange,Laura Park,Charlotte Gatts,Dominic Warren,Robert Kleiman,George Mokua Nyangweso,Michael Ochieng,Thaddaeus Egondi,Kevin Onyango,Truphoso Omollo,Raymond Omollo,Jo Sturgess,Steven Saunders,Elizabeth Allen,Suzanne Gajewski,Valentina Butoescu,Jarmila Hanekova,Coralie Etter,Yerkbulan Kambarov,Siza Mphele,Victoria Sukhinina,Olesya Huzar,Andrey Reshetnikov,Christine Cilliè,Nada Ahmed,Robert Hunt,Corinne Merle,Allanazarova Gulayim,Mansa Mbenga,Zlikha Saparbaevna Baltasheva,Tleubergen Abdrasuliev,Hasmik Margaryan,Utemuratova Gozzal Urgenishbaevna,Alena Skrahina,Natalia Yatskevich,Dzmitry Viatushka,Tatsiana Apanasevich,Aliaksandr Skrahin,Lynette Duckworth,Cindy Narasimooloo,Ndlovu Ellah Lesego,Sharon Motlhako,Mamomoko Ephenia Mashamaite,Evelyn Mojapelo

DOI: https://doi.org/10.1016/S2213-2600(23)00389-2

Abstract:Background: Around 500 000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are needed. Following an interim analysis, we report the final safety and efficacy outcomes of the TB-PRACTECAL trial, evaluating the safety and efficacy of oral regimens for the treatment of rifampicin-resistant tuberculosis. Methods: This open-label, randomised, controlled, multi-arm, multicentre, non-inferiority trial was conducted at seven hospital and community sites in Uzbekistan, Belarus, and South Africa, and enrolled participants aged 15 years and older with pulmonary rifampicin-resistant tuberculosis. Participants were randomly assigned, in a 1:1:1:1 ratio using variable block randomisation and stratified by trial site, to receive 36-80 week standard care; 24-week oral bedaquiline, pretomanid, and linezolid (BPaL); BPaL plus clofazimine (BPaLC); or BPaL plus moxifloxacin (BPaLM) in stage one of the trial, and in a 1:1 ratio to receive standard care or BPaLM in stage two of the trial, the results of which are described here. Laboratory staff and trial sponsors were masked to group assignment and outcomes were assessed by unmasked investigators. The primary outcome was the percentage of participants with a composite unfavourable outcome (treatment failure, death, treatment discontinuation, disease recurrence, or loss to follow-up) at 72 weeks after randomisation in the modified intention-to-treat population (all participants with rifampicin-resistant disease who received at least one dose of study medication) and the per-protocol population (a subset of the modified intention-to-treat population excluding participants who did not complete a protocol-adherent course of treatment (other than because of treatment failure or death) and those who discontinued treatment early because they violated at least one of the inclusion or exclusion criteria). Safety was measured in the safety population. The non-inferiority margin was 12%. This trial is registered with ClinicalTrials.gov, NCT02589782, and is complete. Findings: Between Jan 16, 2017, and March 18, 2021, 680 patients were screened for eligibility, of whom 552 were enrolled and randomly assigned (152 to the standard care group, 151 to the BPaLM group, 126 to the BPaLC group, and 123 to the BPaL group). The standard care and BPaLM groups proceeded to stage two and are reported here, post-hoc analyses of the BPaLC and BPaL groups are also reported. 151 participants in the BPaLM group and 151 in the standard care group were included in the safety population, with 138 in the BPaLM group and 137 in the standard care group in the modified intention-to-treat population. In the modified intention-to-treat population, unfavourable outcomes were reported in 16 (12%) of 137 participants for whom outcome was assessable in the BPaLM group and 56 (41%) of 137 participants in the standard care group (risk difference -29·2 percentage points [96·6% CI -39·8 to -18·6]; non-inferiority and superiority p<0·0001). 34 (23%) of 151 participants receiving BPaLM had adverse events of grade 3 or higher or serious adverse events, compared with 72 (48%) of 151 participants receiving standard care (risk difference -25·2 percentage points [96·6% CI -36·4 to -13·9]). Five deaths were reported in the standard care group by week 72, of which one (COVID-19 pneumonia) was unrelated to treatment and four (acute pancreatitis, suicide, sudden death, and sudden cardiac death) were judged to be treatment-related. Interpretation: The 24-week, all-oral BPaLM regimen is safe and efficacious for the treatment of pulmonary rifampicin-resistant tuberculosis, and was added to the WHO guidance for treatment of this condition in 2022. These findings will be key to BPaLM becoming the preferred regimen for adolescents and adults with pulmonary rifampicin-resistant tuberculosis. Funding: Médecins Sans Frontières.
121. Improving Predictive Value of Phase 2a TB Drug Development Models Through PET/CT Imaging (nexgen EBA)

Yingda Xie,Laura Via,Ray Chen,Lori Dodd,Ying Cai,Paveen Paripati,Lisa Goldfeder,Jill Winter,Kriti Arora,Jing Wang,Veronique De Jagar,Stephanus Malherbe,Taeksun Song,Gerhard Walzl,Andreas Diacon,Clifton Barry III

DOI: https://doi.org/10.1093/ofid/ofy209.012

2018-01-01

Open Forum Infectious Diseases

Abstract:Abstract Background Current Phase 2a methods in tuberculosis (TB) drug development are severely limited in capturing a drug candidate’s sterilizing activity (ability to prevent TB relapse). We hypothesize that sputum-based measurements of current methods fail to capture drug activity in deep TB lesion compartments, where recalcitrant TB populations are sequestered. In our recent marmoset study, we found complementary 14-day PET/CT delta signatures across different TB lesion compartments that distinguish drugs with long-term sterilizing activity (e.g., rifampin and pyrazinamide) versus drugs with primarily early bactericidal activity (e.g., isoniazid) (Figure 1). We proceeded to evaluate this novel PET/CT Phase 2a approach among TB patients, benchmarked by drugs that are well-characterized clinically and pharmacokinetically. Methods HIV-negative patients with smear-positive pulmonary tuberculosis from Cape Town, South Africa were enrolled and randomized to receive a single drug [isoniazid (H), rifampin (R), pyrazinamide (Z), moxifloxacin (M)], a 2-drug regimen (HZ, RZ), or a 4-drug regimen (HRZE, MRZE) for 14 days in an inpatient facility. Primary data points were PET/CT scans evaluated at pretreatment baseline and treatment day 14 (and day 28 in the HRZE arm), and daily overnight sputum for early bactericidal activity measurements. Results From December 2015 to September 2017, 160 participants completed the study, from whom 340 PET/CT scans and 2,238 overnight sputum samples were collected. PET/CT scans from participants demonstrate diversity of lesion architecture and inter-individual variation in PET/CT changes over 14 days of treatment (Figure 2). A preliminary computational algorithm and first- and second-order PET/CT statistics have been developed for initial segmentation and TB lesion categorization of all study scans. Derivation of radiologic signatures by analysis of 14-day PET/CT changes across each lesion type is ongoing; blinded prediction of each participant’s treatment arm based on these signatures is expected by third-quarter 2018. Conclusion If successful, these signatures may be applied within a 14-day Phase 2a framework to evaluate new TB drug candidates and construct TB drug regimens with complementary lesion pharmacokinetics. Disclosures All authors: No reported disclosures.
Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial

L. Guglielmetti,E. Ardizzoni,M. Atger,E. Baudin,E. Berikova,M. Bonnet,E. Chang,S. Cloez,J. M. Coit,V. Cox,B. C. de Jong,C. Delifer,J. M. Do,D. Dos Santos Tozzi,V. Ducher,G. Ferlazzo,M. Gouillou,A. Khan,U. Khan,N. Lachenal,A. N. LaHood,L. Lecca,M. Mazmanian,H. McIlleron,M. Moschioni,K. O’Brien,O. Okunbor,L. Oyewusi,S. Panda,S. B. Patil,P. P. J. Phillips,L. Pichon,P. Rupasinghe,M. L. Rich,N. Saluhuddin,K. J. Seung,M. Tamirat,L. Trippa,M. Cellamare,G. E. Velásquez,S. Wasserman,P. J. Zimetbaum,F. Varaine,C. D. Mitnick

DOI: https://doi.org/10.1186/s13063-021-05491-3

IF: 2.728

2021-09-25

Trials

Abstract:Abstract Background Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. While most MDR/RR-TB patients do not receive treatment, many who do are treated for 18 months or more. A shorter all-oral regimen is currently recommended for only a sub-set of MDR/RR-TB. Its use is only conditionally recommended because of very low-quality evidence underpinning the recommendation. Novel combinations of newer and repurposed drugs bring hope in the fight against MDR/RR-TB, but their use has not been optimized in all-oral, shorter regimens. This has greatly limited their impact on the burden of disease. There is, therefore, dire need for high-quality evidence on the performance of new, shortened, injectable-sparing regimens for MDR-TB which can be adapted to individual patients and different settings. Methods endTB is a phase III, pragmatic, multi-country, adaptive, randomized, controlled, parallel, open-label clinical trial evaluating the efficacy and safety of shorter treatment regimens containing new drugs for patients with fluoroquinolone-susceptible, rifampin-resistant tuberculosis. Study participants are randomized to either the control arm, based on the current standard of care for MDR/RR-TB, or to one of five 39-week multi-drug regimens containing newly approved and repurposed drugs. Study participation in all arms lasts at least 73 and up to 104 weeks post-randomization. Randomization is response-adapted using interim Bayesian analysis of efficacy endpoints. The primary objective is to assess whether the efficacy of experimental regimens at 73 weeks is non-inferior to that of the control. A sample size of 750 patients across 6 arms affords at least 80% power to detect the non-inferiority of at least 1 (and up to 3) experimental regimens, with a one-sided alpha of 0.025 and a non-inferiority margin of 12%, against the control in both modified intention-to-treat and per protocol populations. Discussion The lack of a safe and effective regimen that can be used in all patients is a major obstacle to delivering appropriate treatment to all patients with active MDR/RR-TB. Identifying multiple shorter, safe, and effective regimens has the potential to greatly reduce the burden of this deadly disease worldwide. Trial registration ClinicalTrials.gov Identifier NCT02754765. Registered on 28 April 2016; the record was last updated for study protocol version 3.3, on 27 August 2019.

medicine, research & experimental
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis

Francesca Conradie,Andreas H Diacon,Nosipho Ngubane,Pauline Howell,Daniel Everitt,Angela M Crook,Carl M Mendel,Erica Egizi,Joanna Moreira,Juliano Timm,Timothy D McHugh,Genevieve H Wills,Anna Bateson,Robert Hunt,Christo Van Niekerk,Mengchun Li,Morounfolu Olugbosi,Melvin Spigelman,Nix-TB Trial Team,Nokuphiwa Mvuna,Caryn Upton,Naadira Vanker,Lize Greyling,Michelle Eriksson,Stella Maris Fabiane,Julio Ortiz Canseco,Priya Solanki

DOI: https://doi.org/10.1056/NEJMoa1901814

2020-03-05

Abstract:Background: Patients with highly drug-resistant forms of tuberculosis have limited treatment options and historically have had poor outcomes. Methods: In an open-label, single-group study in which follow-up is ongoing at three South African sites, we investigated treatment with three oral drugs - bedaquiline, pretomanid, and linezolid - that have bactericidal activity against tuberculosis and to which there is little preexisting resistance. We evaluated the safety and efficacy of the drug combination for 26 weeks in patients with extensively drug-resistant tuberculosis and patients with multidrug-resistant tuberculosis that was not responsive to treatment or for which a second-line regimen had been discontinued because of side effects. The primary end point was the incidence of an unfavorable outcome, defined as treatment failure (bacteriologic or clinical) or relapse during follow-up, which continued until 6 months after the end of treatment. Patients were classified as having a favorable outcome at 6 months if they had resolution of clinical disease, a negative culture status, and had not already been classified as having had an unfavorable outcome. Other efficacy end points and safety were also evaluated. Results: A total of 109 patients were enrolled in the study and were included in the evaluation of efficacy and safety end points. At 6 months after the end of treatment in the intention-to-treat analysis, 11 patients (10%) had an unfavorable outcome and 98 patients (90%; 95% confidence interval, 83 to 95) had a favorable outcome. The 11 unfavorable outcomes were 7 deaths (6 during treatment and 1 from an unknown cause during follow-up), 1 withdrawal of consent during treatment, 2 relapses during follow-up, and 1 loss to follow-up. The expected linezolid toxic effects of peripheral neuropathy (occurring in 81% of patients) and myelosuppression (48%), although common, were manageable, often leading to dose reductions or interruptions in treatment with linezolid. Conclusions: The combination of bedaquiline, pretomanid, and linezolid led to a favorable outcome at 6 months after the end of therapy in a high percentage of patients with highly drug-resistant forms of tuberculosis; some associated toxic effects were observed. (Funded by the TB Alliance and others; ClinicalTrials.gov number, NCT02333799.).
[Proceedings: Pulmonary circulation in various heart diseases--with special emphasis on radiographic observation of the pulmonary artery].

K. Masutani,T. Saga,E. Kawasaki,S. Matsui,T. Kin

1975-04-01

Japanese Circulation Journal

Abstract:
Short-course Regimen for Subsequent Treatment of Pulmonary Tuberculosis: A Prospective, Randomized, Controlled Multicenter Clinical Trial in China.

Liping Yan,Xiaohong Kan,Limei Zhu,Kaijin Xu,Jianjun Yin,Li Jie,Yong Li,Ji Yue,Wenyu Cui,Juan Du,Lihua Wang,Shouyong Tan,Xiangao Jiang,Zhong Zeng,Shenghui Xu,Lin Wang,Yu Chen,Weiguo He,Xusheng Gao,Dapeng Bai,Chengjie Zhao,Xiaofeng Yan,Yuyin Zhu,Yumei Fan,Lanpin Xie,Aihua Deng,Qing Zhang,Heping Xiao

DOI: https://doi.org/10.1016/j.clinthera.2018.01.013

IF: 3.637

2018-01-01

Clinical Therapeutics

Abstract:Purpose: We designed a prospective, multicenter, randomized, controlled study to assess a 5-month regimen compared with the standard regimen on previously treated patients with pulmonary tuberculosis (TB). Methods: We enrolled 917 sputum smear-positive patients undergoing additional treatment in 27 major tuberculosis hospitals in China. Patients were randomly assigned to a test group (n -= 626)treated with a 5-month regimen of moxifloxacin, pasiniazid, rifabutin, ethambutol, and pyrazinamide or a reference group (n = 291) treated with an 8-month regimen of isoniazid, rifampicin, and streptomycin. All patients with a favorable response were followed up for 5 years after the end of treatment. Findings: Of the study patients, 61 in the test group and 19 in the reference group had multidrug-resistant (MDR) TB. The treatment success rate in the study group was 74.12%, which was significantly higher than the 67.70% in the reference group (P = 0.04), whereas the treatment success rate of patients with MDR-TB was not significantly different between the test and reference groups (70.5% vs 63.1%, P =0.79). The adverse effects rates in the test and reference groups were 7.4% and 3.1%, respectively (P = .01). The difference in the TB recurrence rates between the group arm (9.6%) and the reference group (21.8%) was statistically significant (P < 0.001). (C) 2018 Elsevier HS Journals, Inc. All rights reserved.
Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease

Connie A Haley,Marcos C Schechter,David Ashkin,Charles A Peloquin,J Peter Cegielski,Barbara B Andrino,Marcos Burgos,Lori A Caloia,Lisa Chen,Angel Colon-Semidey,Malini B DeSilva,Shireesha Dhanireddy,Susan E Dorman,Felicia F Dworkin,Heidi Hammond-Epstein,Alice V Easton,James T Gaensbauer,Bijan Ghassemieh,Maria E Gomez,David Horne,Supriya Jasuja,Betsy A Jones,Leonard J Kaplan,Asharaf Edward Khan,Elizabeth Kracen,Sarah Labuda,Karen M Landers,Alfred A Lardizabal,Maria T Lasley,David M Letzer,Vinicius K Lopes,Ronald J Lubelchek,C Patricia Macias,Aimee Mihalyov,Elizabeth Ann Misch,Jason A Murray,Masahiro Narita,Diana M Nilsen,Megan J Ninneman,Lynne Ogawa,Alawode Oladele,Melissa Overman,Susan M Ray,Kathleen A Ritger,Marie-Claire Rowlinson,Nadya Sabuwala,Thomas M Schiller,Lawrence E Schwartz,Christopher Spitters,Douglas B Thomson,Rene Rico Tresgallo,Patrick Valois,Neela D Goswami,BPaL Implementation Group,Rocio Agraz-Lara,Amina Ahmed,Ana Alvarez,Lisa Armitage,Pennan Barry,Robert Belknap,John Bernardo,Mary Bravo,Sarah Brode,Elizabeth Burden,Joseph Burzynski,Caralee Caplan-Shaw,Ken Castro,Terry Chorba,William Connors,Victoria Cook,Andrea Cruz,Charles Daley,Shom Dasgupta,Sonia Dhingra,Thomas Dobbs,Ellen Elmore,Frank Erwin,Vincent Escuyer,Christina Fiske,Beth Gadkowski,German Henestroza,Julie Higashi,Shereen Katrak,Chris Keh,Amanda Khalil,Lilian Kigonya,Michael Lauzardo,Sapna Morris,Sonal Munsiff,Scott Nabity,Margaret Oxtoby,Amee Patrawalla,Allison Phillips,Ann Raftery,Caitlin Reed,Brian Rock,Kelly Russo,Harleen Sahini,Paul Saleeb,Roberto Santos,Barbara Seaworth,Joanna Shaw-KaiKai,Jeff Starke,Jason Stout,Wesley Stubblefield,Zelalem Temesgen,Keziah Thomas,Jeffrey Tornheim,Caryn Upton,Daniel Urbine,Shu-Hua Wang,Jon Warkentin,Risa Webb,John Wilson,Johnathan Wortham,And Salinia Yu,Claudia Altman,Irfan Hafiz,Deepa Prabhakar,William Bowler

DOI: https://doi.org/10.1093/cid/ciad312

2023-10-05

Abstract:Background: Rifampin-resistant tuberculosis is a leading cause of morbidity worldwide; only one-third of persons start treatment, and outcomes are often inadequate. Several trials demonstrate 90% efficacy using an all-oral, 6-month regimen of bedaquiline, pretomanid, and linezolid (BPaL), but significant toxicity occurred using 1200-mg linezolid. After US Food and Drug Administration approval in 2019, some US clinicians rapidly implemented BPaL using an initial 600-mg linezolid dose adjusted by serum drug concentrations and clinical monitoring. Methods: Data from US patients treated with BPaL between 14 October 2019 and 30 April 2022 were compiled and analyzed by the BPaL Implementation Group (BIG), including baseline examination and laboratory, electrocardiographic, and clinical monitoring throughout treatment and follow-up. Linezolid dosing and clinical management was provider driven, and most patients had linezolid adjusted by therapeutic drug monitoring. Results: Of 70 patients starting BPaL, 2 changed to rifampin-based therapy, 68 (97.1%) completed BPaL, and 2 of the 68 (2.9%) experienced relapse after completion. Using an initial 600-mg linezolid dose daily adjusted by therapeutic drug monitoring and careful clinical and laboratory monitoring for adverse effects, supportive care, and expert consultation throughout BPaL treatment, 3 patients (4.4%) with hematologic toxicity and 4 (5.9%) with neurotoxicity required a change in linezolid dose or frequency. The median BPaL duration was 6 months. Conclusions: BPaL has transformed treatment for rifampin-resistant or intolerant tuberculosis. In this cohort, effective treatment required less than half the duration recommended in 2019 US guidelines for drug-resistant tuberculosis. Use of individualized linezolid dosing and monitoring likely enhanced safety and treatment completion. The BIG cohort demonstrates that early implementation of new tuberculosis treatments in the United States is feasible.
Remarks by Louis W. Sullivan, MD, Secretary of Health and Human Services, at the sixth annual meeting of the Association for Academic Minority Physicians, October 23-25, 1992, Washington, DC.

L. Sullivan

Abstract:
Randomised trial to evaluate the effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant or treatment intolerant/non-responsive multidrug-resistant pulmonary tuberculosis: study protocol

Chandrasekaran Padmapriyadarsini,Bella Devaleenal,C Ponnuraja,Balaji Ramraj,Rupak Singla,Malik Parmar,Sanjay Mattoo,Sudarsan Mandal

DOI: https://doi.org/10.1136/bmjopen-2021-058606

IF: 3.006

2022-08-29

BMJ Open

Abstract:Introduction: Drug-resistant tuberculosis (DR-TB) is a global public health problem. Patients suffer for months if undiagnosed or treated inadequately, transmitting DR-TB in the community before succumbing to the disease. Early diagnosis, prompt treatment initiation and completion play a significant role in treatment success. However, extended regimens with injectable result in poor treatment adherence and outcomes. Our objective is to evaluate the effectiveness, safety and tolerability of various doses and duration of linezolid (LZD) in combination with bedaquiline (BDQ) and pretomanid (Pa) after 26 weeks of treatment in adults with pre-extensively drug-resistant or treatment intolerant/non-responsive multidrug-resistant pulmonary TB. Methods and analysis: A multicentric, randomised pragmatic clinical trial in India will enrol participants in one of the three arms-control arm (arm 1): BDQ, Pa and LZD 600 mg daily for 26 weeks or intervention arms (arm 2): BDQ, Pa and LZD 600 mg for 9 weeks followed by 300 mg for 17 weeks or arm 3: BDQ, Pa and LZD 600 mg for 13 weeks followed by 300 mg for 13 weeks. The primary endpoint is the proportion of patients with favourable outcomes as sustained cure and treatment completion. The secondary endpoint is unfavourable outcomes, including deaths, treatment failure, toxicity/adverse events and lost to follow-up till 48 weeks post-treatment. Ethics and dissemination: The study has been approved by the ethics committees of participating institutes and the National Institute for Research in TB. The trial results will help establish evidence towards a safe and effective dose of LZD that can be used in a fully, all-oral short course regimen for highly DR-TB patients. The results of this study will be shared with the National TB Elimination Programme of the country and the WHO guidelines development group through publications and dissemination meetings. Trial registration number: NCT05040126.
[Cardiovascular system involution - pre-arteriosclerotic factors].

J. Cieślak

1981-04-15

Abstract:
Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial

Ruth L Goodall,Sarah K Meredith,Andrew J Nunn,Adamu Bayissa,Anuj K Bhatnagar,Gay Bronson,Chen-Yuan Chiang,Francesca Conradie,Meera Gurumurthy,Bruce Kirenga,Nana Kiria,Daniel Meressa,Ronelle Moodliar,Gopalan Narendran,Nosipho Ngubane,Mohammed Rassool,Karen Sanders,Rajesh Solanki,S Bertel Squire,Gabriela Torrea,Bazarragchaa Tsogt,Elena Tudor,Armand Van Deun,I D Rusen,Oyunchimeg Adilaa,Sofia Alexandru,Katharine Bellenger,Jaclyn Bennet,Deborah Bennet,Priyanka Bindroo,Ghanshyam Borisagar,Claire Cook,Doljinsuren Dalai,Andrew Davis,Bouke de Jong,Wendy Dodds,Lynette Duckworth,Nonhlanhla Gahima,Belay Gebreegziabher,Anne Goldfeld,Mahmud Hanifa,Gareth Hughes,Ivan Kimuli,Jan Komrska,Nino Lomtadze,Brendan Murphy,Thando Mwelase,Joanitah Nalunjogi,Leena Patel,Irina Pirlog,Ishmael Qawiy,Mary Rauchenberger,Leen Rigouts,Carol Roach,Laura Rosu,Ezio Santos-Filho,Thirumaran Senguttuvan,Million Sisay,Rathinam Sridhar,Vignes Srinivasulu,Mekonnen Teferi,Helen Teklu,Narangarav Tsegeen,Odette van Amsterdam,Lisa White,Johanna Whitney,Chuluunbaatar Zagd

DOI: https://doi.org/10.1016/s0140-6736(22)02078-5

IF: 202.731

2022-11-01

The Lancet

Abstract:BACKGROUND: The STREAM stage 1 trial showed that a 9-month regimen for the treatment of rifampicin-resistant tuberculosis was non-inferior to the 20-month 2011 WHO-recommended regimen. In STREAM stage 2, we aimed to compare two bedaquiline-containing regimens with the 9-month STREAM stage 1 regimen.METHODS: We did a randomised, phase 3, non-inferiority trial in 13 hospital clinics in seven countries, in individuals aged 15 years or older with rifampicin-resistant tuberculosis without fluoroquinolone or aminoglycoside resistance. Participants were randomly assigned 1:2:2:2 to the 2011 WHO regimen (terminated early), a 9-month control regimen, a 9-month oral regimen with bedaquiline (primary comparison), or a 6-month regimen with bedaquiline and 8 weeks of second-line injectable. Randomisations were stratified by site, HIV status, and CD4 count. Participants and clinicians were aware of treatment-group assignments, but laboratory staff were masked. The primary outcome was favourable status (negative cultures for Mycobacterium tuberculosis without a preceding unfavourable outcome) at 76 weeks; any death, bacteriological failure or recurrence, and major treatment change were considered unfavourable outcomes. All comparisons used groups of participants randomly assigned concurrently. For non-inferiority to be shown, the upper boundary of the 95% CI should be less than 10% in both modified intention-to-treat (mITT) and per-protocol analyses, with prespecified tests for superiority done if non-inferiority was shown. This trial is registered with ISRCTN, ISRCTN18148631.FINDINGS: Between March 28, 2016, and Jan 28, 2020, 1436 participants were screened and 588 were randomly assigned. Of 517 participants in the mITT population, 133 (71%) of 187 on the control regimen and 162 (83%) of 196 on the oral regimen had a favourable outcome: a difference of 11·0% (95% CI 2·9-19·0), adjusted for HIV status and randomisation protocol (p<0·0001 for non-inferiority). By 76 weeks, 108 (53%) of 202 participants on the control regimen and 106 (50%) of 211 allocated to the oral regimen had an adverse event of grade 3 or 4; five (2%) participants on the control regimen and seven (3%) on the oral regimen had died. Hearing loss (Brock grade 3 or 4) was more frequent in participants on the control regimen than in those on the oral regimen (18 [9%] vs four [2%], p=0·0015). Of 134 participants in the mITT population who were allocated to the 6-month regimen, 122 (91%) had a favourable outcome compared with 87 (69%) of 127 participants randomly assigned concurrently to the control regimen (adjusted difference 22·2%, 95% CI 13·1-31·2); six (4%) of 143 participants on the 6-month regimen had grade 3 or 4 hearing loss.INTERPRETATION: Both bedaquiline-containing regimens, a 9-month oral regimen and a 6-month regimen with 8 weeks of second-line injectable, had superior efficacy compared with a 9-month injectable-containing regimen, with fewer cases of hearing loss.FUNDING: USAID and Janssen Research & Development.

medicine, general & internal
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial

Myungsun Lee,Jeongha Mok,Deog Kyeom Kim,Tae Sun Shim,Won-Jung Koh,Doosoo Jeon,Taehoon Lee,Seung Heon Lee,Ju Sang Kim,Jae Seuk Park,Ji Yeon Lee,Song Yee Kim,Jae Ho Lee,Kyung-Wook Jo,Byung Woo Jhun,Young Ae Kang,Joong Hyun Ahn,Chang-Ki Kim,Soyoun Shin,Taeksun Song,Sung Jae Shin,Young Ran Kim,Heejung Ahn,Seokyung Hahn,Ho Jeong Won,Ji Yeon Jang,Sang Nae Cho,Jae-Joon Yim

DOI: https://doi.org/10.1186/s13063-018-3053-1

IF: 2.728

2019-01-16

Trials

Abstract:Background: Treatment success rates of multidrug-resistant tuberculosis (MDR-TB) remain unsatisfactory, and long-term use of second-line anti-TB drugs is accompanied by the frequent occurrence of adverse events, low treatment compliance, and high costs. The development of new efficient regimens with shorter treatment durations for MDR-TB will solve these issues and improve treatment outcomes. Methods: This study is a phase II/III, multicenter, randomized, open-label clinical trial of non-inferiority design comparing a new regimen to the World Health Organization-endorsed conventional regimen for fluoroquinolone-sensitive MDR-TB. The control arm uses a conventional treatment regimen with second-line drugs including injectables for 20-24 months. The investigational arm uses a new shorter regimen including delamanid, linezolid, levofloxacin, and pyrazinamide for 9 or 12 months depending on time to sputum culture conversion. The primary outcome is the treatment success rate at 24 months after treatment initiation. Secondary outcomes include time to sputum culture conversion on liquid and solid media, proportions of sputum culture conversion on liquid media after 2 and 6 months of treatment, treatment success rate according to pyrazinamide resistance, and occurrence of adverse events grade 3 and above as evaluated by the Common Terminology Criteria for Adverse Events. Based on an α = 0.025 level of significance (one-sided test), a power of 80%, and a < 10% difference in treatment success rate between the control and investigational arms (80% vs. 70%) when the anticipated actual success rate in the treatment group is assumed to be 90%, the number of participants needed per arm to show non-inferiority of the investigational regimen was calculated as 48. Additionally, assuming the proportion of fluoroquinolone-susceptible MDR-TB among participants as 50%, and 5% loss to follow-up, the number of participants is calculated as N/( 0.50 × 0.95), resulting in 102 persons per group (204 in total). Discussion: This trial will reveal the effectiveness and safety of a new shorter regimen comprising four oral drugs, including delamanid, linezolid, levofloxacin, and pyrazinamide, for the treatment of fluoroquinolone-sensitive MDR-TB. Results from this trial will provide evidence for adopting a shorter and more convenient treatment regimen for MDR-TB. Trial registration: ClincalTrials.gov, NCT02619994 . Registered on 2 December 2015.
An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study)

Aliasgar Esmail,Suzette Oelofse,Carl Lombard,Rubeshan Perumal,Linda Mbuthini,Akhter Goolam Mahomed,Ebrahim Variava,John Black,Patrick Oluboyo,Nelile Gwentshu,Eric Ngam,Tertius Ackerman,Linde Marais,Lynelle Mottay,Stuart Meier,Anil Pooran,Michele Tomasicchio,Julian Te Riele,Brigitta Derendinger,Norbert Ndjeka,Gary Maartens,Robin Warren,Neil Martinson,Keertan Dheda

DOI: https://doi.org/10.1164/rccm.202107-1779OC

2022-05-15

Abstract:Rationale: Improving treatment outcomes while reducing drug toxicity and shortening the treatment duration to ∼6 months remains an aspirational goal for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB). Objectives: To conduct a multicenter randomized controlled trial in adults with MDR/RR-TB (i.e., without resistance to fluoroquinolones or aminoglycosides). Methods: Participants were randomly assigned (1:1 ratio) to a ∼6-month all-oral regimen that included levofloxacin, bedaquiline, and linezolid, or the standard-of-care (SOC) ⩾9-month World Health Organization (WHO)-approved injectable-based regimen. The primary endpoint was a favorable WHO-defined treatment outcome (which mandates that prespecified drug substitution is counted as an unfavorable outcome) 24 months after treatment initiation. The trial was stopped prematurely when bedaquiline-based therapy became the standard of care in South Africa. Measurements and Main Results: In total, 93 of 111 randomized participants (44 in the comparator arm and 49 in the interventional arm) were included in the modified intention-to-treat analysis; 51 (55%) were HIV coinfected (median CD4 count, 158 cells/ml). Participants in the intervention arm were 2.2 times more likely to experience a favorable 24-month outcome than participants in the SOC arm (51% [25 of 49] vs. 22.7% [10 of 44]; risk ratio, 2.2 [1.2-4.1]; P = 0.006). Toxicity-related drug substitution occurred more frequently in the SOC arm (65.9% [29 of 44] vs. 34.7% [17 of 49]; P = 0.001)], 82.8% (24 of 29) owing to kanamycin (mainly hearing loss; replaced by bedaquiline) in the SOC arm, and 64.7% (11 of 17) owing to linezolid (mainly anemia) in the interventional arm. Adverse event-related treatment discontinuation in the safety population was more common in the SOC arm (56.4% [31 of 55] vs. 32.1% [17 of 56]; P = 0.007). However, grade 3 adverse events were more common in the interventional arm (55.4% [31 of 56] vs. 32.7 [18 of 55]; P = 0.022). Culture conversion was significantly better in the intervention arm (hazard ratio, 2.6 [1.4-4.9]; P = 0.003) after censoring those with bedaquiline replacement in the SOC arm (and this pattern remained consistent after censoring for drug replacement in both arms; P = 0.01). Conclusions: Compared with traditional injectable-containing regimens, an all-oral 6-month levofloxacin, bedaquiline, and linezolid-containing MDR/RR-TB regimen was associated with a significantly improved 24-month WHO-defined treatment outcome (predominantly owing to toxicity-related drug substitution). However, drug toxicity occurred frequently in both arms. These findings inform strategies to develop future regimens for MDR/RR-TB.Clinical trial registered with www.clinicaltrials.gov (NCT02454205).
A Modified BPaL Regimen for Tuberculosis Treatment replaces Linezolid with Inhaled Spectinamides

Malik Zohaib Ali,Taru S Dutt,Amy MacNeil,Amanda Walz,Johnathan Patterson,Camron Pearce,Ha Lam,Jamie S Philp,Richard Lee,Jiuyu Liu,Gregory Thomas Robertson,Anthony J Hickey,Bernd Meibohm,Mercedes Gonzalez-Juarrero

DOI: https://doi.org/10.1101/2023.11.16.567434

2024-06-11

Abstract:The Nix-TB clinical trial evaluated a new 6-month regimen containing three-oral-drugs; bedaquiline (B), pretomanid (Pa) and linezolid (L) (BPaL regimen) for treatment of tuberculosis (TB). This regimen achieved remarkable results as almost 90% of the multidrug resistant (MDR) or extensively drug resistant (XDR) TB participants were cured but many patients also developed severe adverse events (AEs). The AEs were associated with the long-term administration of the protein synthesis inhibitor linezolid. Spectinamide 1599 is also a protein synthesis inhibitor of Mycobacterium tuberculosis with an excellent safety profile but which lacks oral bioavailability. Here, we propose to replace L in the BPaL regimen with spectinamide (S) administered via inhalation and we demonstrate that inhaled spectinamide 1599, combined with BPa (BPaS regimen) has similar efficacy to that of BPaL regimen while simultaneously avoiding the L-associated AEs. The BPaL and BPaS regimens were compared in the BALB/c and C3HeB/FeJ murine chronic TB efficacy models. After 4-weeks of treatment, both regimens promoted equivalent bactericidal effect in both TB murine models. However, treatment with BPaL resulted in significant weight loss and the complete blood count suggested development of anemia. These effects were not similarly observed in mice treated with BPaS. BPaL and BPa, but no the BPaS treatment, also decreased myeloid to erythroid ratio suggesting the S in the BPaS regimen was able to recover this effect. Moreover, the BPaL also increased concentration of proinflammatory cytokines in bone marrow compared to mice receiving BPaS regimen. During therapy both regimens improved the lung lesion burden, reduced neutrophil and cytotoxic T cells counts while increased the number of B and helper and regulatory T cells. These combined data suggest that inhaled spectinamide 1599 combined with BPa is an effective TB regimen that avoids L-associated AEs.

Microbiology
Triage test for all-oral drug-resistant tuberculosis (DR-TB) regimen: a phase IV study to assess effectiveness, feasibility, acceptability and cost-effectiveness of the Xpert MTB/XDR assay for rapid triage and treatment of DR-TB

Kogieleum Naidoo,Anushka Naidoo,Alash'le G Abimiku,Everdina W Tiemersma,Agnes Gebhard,Sabine M Hermans,Derek J Sloan,Morten Ruhwald,Sophia B Georghiou,Evaezi Okpokoro,Aderonke Agbaje,Kalkidan Yae,Getachew Tollera,Shewki Moga,Hannelise Feyt,Takondwa Kachoka,Marothi P Letsoalo,Andrea M Cabibbe,Rubeshan Perumal,Letitia Shunmugam,Daniela M Cirillo,Salah Foraida,Wilber Sabiiti,Nyanda Elias Ntinginya,Bariki Mtafya,Ahmed Bedru,Stephen H Gillespie

DOI: https://doi.org/10.1136/bmjopen-2024-084722

IF: 3.006

2024-11-30

BMJ Open

Abstract:Introduction The TriAD study will assess the Xpert MTB/XDR (Xpert XDR; Cepheid) assay to detect tuberculosis (TB) drug resistance in sputum testing positive for TB to rapidly triage and treat patients with a short all-oral treatment regimen. Methods and analysis In this study, approximately 4800 Xpert MTB/RIF or Ultra MTB-positive patients (irrespective of rifampicin (RIF) resistance (RR) status) from several clinical sites across South Africa, Nigeria and Ethiopia will be enrolled over 18–24 months and followed-up for approximately 6 months post-TB treatment completion. Participants will be enrolled into one of two cohorts based on Xpert MTB/RIF and Xpert XDR results: Mycobacterium tuberculosis ( M.tb ) positive participants with RR in Cohort 1 (n=880) and M.tb positive RIF susceptible TB patients with isoniazid mono-resistance irrespective of presence of resistance to fluoroquinolones, second-line injectable drugs or ethionamide in Cohort 2 (n=400). Cohort 1 will be compared with historical cohorts from each implementing sites. The primary study outcomes include time to initiation of an appropriate treatment regimen by resistance profile and the proportion of patients with favourable treatment outcomes compared with historical cohorts from each of the implementing sites. Secondary outcomes include feasibility, acceptability and cost-effectiveness of this approach to inform policies and guidelines for programmatic implementation of this triage and treat model for drug-resistant tuberculosis management. Utility of the tuberculosis molecular bacterial load assay (TB-MBLA) for real-time treatment response assessment will also be evaluated. Ethics and dissemination The University of KwaZulu-Natal Biomedical Research Ethics Committee (BREC) and local research committees have provided ethical review and approval (BREC/00002654/2021, HREC 210805, NHREC/01/01/2007 and EPHI-IRB-459–2022). The South African Health Products Regulatory Authority (SAHPRA) have granted regulatory approval for the TRiAD Study (SAHPRA MD20211001). Trial results will be disseminated through conference presentations, peer-reviewed publications and the clinical trial registry. Trial registration number Clinicaltrials.gov; Trial registration number: NCT05175794; South African National Clinical Trials Register (SANCTR DOH-27-012022-4720)

medicine, general & internal
Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in China

Yanhua Song,Wei Shu,Yi Pei,Juan Du,Guihui Wu,Hua Wang,Fengling Mi,Fangchao Liu,Liping Ma,Li Xie,Zhongshun Kong,Xiaoguang Wu,Rongmei Liu,Hongmei Chen,Hua Li,Qiping Ge,Lihui Nie,Zizheng Lv,Xuerui Huang,Mingwu Li,Mingying Jiang,Xiaohong Chen,Qingshan Cai,Wei Chen,Yanmei Liu,Yanfang Miao,Yan Tang,Yu Chen,Shujun Geng,Quanying Zhou,Yuhong Liu,Yu Pang,Mengqiu Gao

DOI: https://doi.org/10.1186/s12916-024-03633-3

2024-09-19

Abstract:Background: We concurrently developed a prospective study to assess clinical outcomes among patients receiving 9-month bedaquiline (BDQ)-containing regimens, aiming to provide valuable data on the use of this short-course regimen in China. Methods: This open-label, randomized, controlled, multicenter, non-inferiority trial was conducted at sixteen hospitals, and enrolled participants aged 18 years and older with pulmonary rifampicin/multidrug tuberculosis. Participants were randomly assigned, in a 1:1 ratio. Individuals within the standard-regimen group received 6 months of BDQ, linezolid, levofloxacin, clofazimine, and cycloserine plus 12 months of levofloxacin, and any three potentially effective drugs from clofazimine, cycloserine pyrazinamide, ethambutol and protionamide, whereas individuals within shorter-regimen group received 9 months of BDQ, linezolid, levofloxacin, clofazimine and cycloserine. The primary outcome was the percentage of participants with a composite unfavorable outcome (treatment failure, death, treatment discontinuation, or loss to follow-up) by the end of the treatment course after randomization in the modified intention-to-treat population. The noninferiority margin was 10%. This trial was registered with www.chictr.org.cn , ChiCTR2000029012. Results: Between Jan 1, 2020, and Dec 31, 2023, 264 were screened and randomly assigned, 132 of 264 participants were assigned to the standard-regimen group and 132 were assigned to the shorter-regimen. Thirty-three (12.55%) of 264 participants were excluded from the modified intention-to-treat analysis. As a result, 231 participants were included in the modified intention-to-treat analysis (116 in the standard-regimen group and 115 in the shorter-regimen group).In the modified intention-to-treat population, unfavorable outcomes were reported in 19 (16.5%) of 115 participants for whom the outcome was assessable in the shorter-regimen group and 26 (22.4%) of 116 participants in the standard care group (risk difference 5.9 percentage points (97.5% CI - 5.8 to 17.5)). One death was reported in the standard-regimen group. The incidence of QTcF prolongation in the shorter-regimen group (22.6%, 26/115) was similar to the standard-regimen group (24.1%, 28/116). Conclusions: The 9-month, all-oral regimen is safe and efficacious for the treatment of pulmonary rifampicin/multidrug-resistant tuberculosis. The high incidence of QTc prolongation associated with the use of BDQ highlights the urgent need of routine electrocardiogram monitoring under treatment with BDQ-containing regimens in the Chinese population.
Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis

Si-Yang Li,Sandeep Tyagi,Heena Soni,Fabrice Betoudji,Paul J Converse,Khisimuzi Mdluli,Anna M Upton,Nader Fotouhi,David Barros-Aguirre,Lluís Ballell,Elena Jimenez-Navarro,Eric L Nuermberger,Paul J. Converse,Anna M. Upton,Eric L. Nuermberger

DOI: https://doi.org/10.1128/aac.01562-23

IF: 5.938

2024-02-22

Antimicrobial Agents and Chemotherapy

Abstract:ABSTRACT The combination of bedaquiline, pretomanid, and linezolid (BPaL) has become a preferred regimen for treating multidrug- and extensively drug-resistant tuberculosis (TB). However, treatment-limiting toxicities of linezolid and reports of emerging bedaquiline and pretomanid resistance necessitate efforts to develop new short-course oral regimens. We recently found that the addition of GSK2556286 increases the bactericidal and sterilizing activity of BPa-containing regimens in a well-established BALB/c mouse model of tuberculosis. Here, we used this model to evaluate the potential of new regimens combining bedaquiline or the more potent diarylquinoline TBAJ-587 with GSK2556286 and the DprE1 inhibitor TBA-7371, all of which are currently in early-phase clinical trials. We found the combination of bedaquiline, GSK2556286, and TBA-7371 to be more active than the first-line regimen and nearly as effective as BPaL in terms of bactericidal and sterilizing activity. In addition, we found that GSK2556286 and TBA-7371 were as effective as pretomanid and the novel oxazolidinone TBI-223 when either drug pair was combined with TBAJ-587 and that the addition of GSK2556286 increased the bactericidal activity of the TBAJ-587, pretomanid, and TBI-223 combination. We conclude that GSK2556286 and TBA-7371 have the potential to replace pretomanid, an oxazolidinone, or both components, in combination with bedaquiline or TBAJ-587.

pharmacology & pharmacy,microbiology
A systematic efficacy analysis of tuberculosis treatment with BPaL‐containing regimens using a multiscale modeling approach

Maral Budak,Laura E. Via,Danielle M. Weiner,Clifton E. Barry,Pariksheet Nanda,Gabrielle Michael,Khisimuzi Mdluli,Denise Kirschner,Clifton E. Barry III

DOI: https://doi.org/10.1002/psp4.13117

2024-02-26

CPT Pharmacometrics & Systems Pharmacology

Abstract:Tuberculosis (TB) is a life‐threatening infectious disease. The standard treatment is up to 90% effective; however, it requires the administration of four antibiotics (isoniazid, rifampicin, pyrazinamide, and ethambutol [HRZE]) over long time periods. This harsh treatment process causes adherence issues for patients because of the long treatment times and a myriad of adverse effects. Therefore, the World Health Organization has focused goals of shortening standard treatment regimens for TB in their End TB Strategy efforts, which aim to reduce TB‐related deaths by 95% by 2035. For this purpose, many novel and promising combination antibiotics are being explored that have recently been discovered, such as the bedaquiline, pretomanid, and linezolid (BPaL) regimen. As a result, testing the number of possible combinations with all possible novel regimens is beyond the limit of experimental resources. In this study, we present a unique framework that uses a primate granuloma modeling approach to screen many combination regimens that are currently under clinical and experimental exploration and assesses their efficacies to inform future studies. We tested well‐studied regimens such as HRZE and BPaL to evaluate the validity and accuracy of our framework. We also simulated additional promising combination regimens that have not been sufficiently studied clinically or experimentally, and we provide a pipeline for regimen ranking based on their efficacies in granulomas. Furthermore, we showed a correlation between simulation rankings and new marmoset data rankings, providing evidence for the credibility of our framework. This framework can be adapted to any TB regimen and can rank any number of single or combination regimens.

pharmacology & pharmacy
A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis

A Dierig,M Hoelscher,S Schultz,L Hoffmann,A Jarchow-MacDonald,E M Svensson,L Te Brake,R Aarnoutse,M Boeree,T D McHugh,L M Wildner,X Gong,Ppj Phillips,L T Minja,N Ntinginya,S Mpagama,A Liyoyo,R S Wallis,M Sebe,F A Mhimbira,B Mbeya,M Rassool,L Geiter,Y L Cho,N Heinrich

DOI: https://doi.org/10.1186/s13063-023-07354-5

IF: 2.728

2023-06-06

Trials

Abstract:Background: Linezolid is an effective, but toxic anti-tuberculosis drug that is currently recommended for the treatment of drug-resistant tuberculosis. Improved oxazolidinones should have a better safety profile, while preserving efficacy. Delpazolid is a novel oxazolidinone developed by LegoChem Biosciences Inc. that has been evaluated up to phase 2a clinical trials. Since oxazolidinone toxicity can occur late in treatment, LegoChem Biosciences Inc. and the PanACEA Consortium designed DECODE to be an innovative dose-ranging study with long-term follow-up for determining the exposure-response and exposure-toxicity relationship of delpazolid to support dose selection for later studies. Delpazolid is administered in combination with bedaquiline, delamanid and moxifloxacin. Methods: Seventy-five participants with drug-sensitive, pulmonary tuberculosis will receive bedaquiline, delamanid and moxifloxacin, and will be randomized to delpazolid dosages of 0 mg, 400 mg, 800 mg, 1200 mg once daily, or 800 mg twice daily, for 16 weeks. The primary efficacy endpoint will be the rate of decline of bacterial load on treatment, measured by MGIT liquid culture time to detection from weekly sputum cultures. The primary safety endpoint will be the proportion of oxazolidinone class toxicities; neuropathy, myelosuppression, or tyramine pressor response. Participants who convert to negative liquid media culture by week 8 will stop treatment after the end of their 16-week course and will be observed for relapse until week 52. Participants who do not convert to negative culture will receive continuation phase treatment with rifampicin and isoniazid to complete a six-month treatment course. Discussion: DECODE is an innovative dose-finding trial, designed to support exposure-response modelling for safe and effective dose selection. The trial design allows assessment of occurrence of late toxicities as observed with linezolid, which is necessary in clinical evaluation of novel oxazolidinones. The primary efficacy endpoint is the change in bacterial load, an endpoint conventionally used in shorter dose-finding trials. Long-term follow-up after shortened treatment is possible through a safety rule excluding slow-and non-responders from potentially poorly performing dosages. Trial registration: DECODE was registered in ClinicalTrials.gov before recruitment start on 22 October 2021 (NCT04550832).

Treatment of diverticulitis; medical management & surgical management.

Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

121. Improving Predictive Value of Phase 2a TB Drug Development Models Through PET/CT Imaging (nexgen EBA)

Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial

Treatment of Highly Drug-Resistant Pulmonary Tuberculosis

[Proceedings: Pulmonary circulation in various heart diseases--with special emphasis on radiographic observation of the pulmonary artery].

Short-course Regimen for Subsequent Treatment of Pulmonary Tuberculosis: A Prospective, Randomized, Controlled Multicenter Clinical Trial in China.

Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease

Remarks by Louis W. Sullivan, MD, Secretary of Health and Human Services, at the sixth annual meeting of the Association for Academic Minority Physicians, October 23-25, 1992, Washington, DC.

Randomised trial to evaluate the effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant or treatment intolerant/non-responsive multidrug-resistant pulmonary tuberculosis: study protocol

[Cardiovascular system involution - pre-arteriosclerotic factors].

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial

An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study)

A Modified BPaL Regimen for Tuberculosis Treatment replaces Linezolid with Inhaled Spectinamides

Triage test for all-oral drug-resistant tuberculosis (DR-TB) regimen: a phase IV study to assess effectiveness, feasibility, acceptability and cost-effectiveness of the Xpert MTB/XDR assay for rapid triage and treatment of DR-TB

Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in China

Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis

A systematic efficacy analysis of tuberculosis treatment with BPaL‐containing regimens using a multiscale modeling approach